Media Room

Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this role, Dr. Lin...

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting....

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018. Cash and investments in marketable securities at September 30, 2018 were...